Sintalica Bioscience is a drug discovery company with a focus on Psilocybin and tryptamine derivatives for psychedelic-assisted therapies. Their expertise lies in synthesizing psychedelics, formulating drugs, and developing new treatments for a variety of health conditions. The team comprises experienced professionals who are up-to-date with the latest drug developments.
The startup's specialization in addictions and mental health aligns with the growing interest and investment in mental wellness. The unique market positioning of Sintalica within the rapidly evolving psychedelics industry offers potential for substantial growth and impact on health care.
While the founding date, industries, headquarters, last investment, and investors are not specified in the available information, the focus on psychedelic-assisted therapies in the context of mental health and addiction treatment presents an intriguing investment opportunity. The potential of Sintalica Bioscience to address unmet needs in the mental health space makes it an attractive prospect for venture capital firms seeking to support innovative solutions in the healthcare sector.
